Trade Lineage Cell Therapeutics, Inc. - LCTX CFD

Add to favourite

1.14

2.56%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.05

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Lineage Cell Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	1.17
Open*	1.2
1-Year Change*	-11.76%
Day's Range*	1.12 - 1.2
52 wk Range	0.90-1.57
Average Volume (10 days)	752.15K
Average Volume (3 months)	12.62M
Market Cap	188.99M
P/E Ratio	-100.00K
Shares Outstanding	174.99M
Revenue	8.77M
EPS	-0.13
Dividend (Yield %)	N/A
Beta	1.24
Next Earnings Date	Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	1.17	-0.07	-5.65%	1.24	1.26	1.16
Apr 17, 2024	1.25	0.11	9.65%	1.14	1.29	1.13
Apr 16, 2024	1.13	-0.09	-7.38%	1.22	1.22	1.12
Apr 15, 2024	1.23	-0.03	-2.38%	1.26	1.28	1.20
Apr 12, 2024	1.29	-0.10	-7.19%	1.39	1.39	1.27
Apr 11, 2024	1.38	0.03	2.22%	1.35	1.42	1.31
Apr 10, 2024	1.33	0.02	1.53%	1.31	1.38	1.30
Apr 9, 2024	1.37	-0.02	-1.44%	1.39	1.43	1.31
Apr 8, 2024	1.43	0.04	2.88%	1.39	1.44	1.36
Apr 5, 2024	1.37	-0.05	-3.52%	1.42	1.44	1.36
Apr 4, 2024	1.41	0.08	6.02%	1.33	1.53	1.33
Apr 3, 2024	1.35	-0.02	-1.46%	1.37	1.39	1.29
Apr 2, 2024	1.37	0.00	0.00%	1.37	1.41	1.34
Apr 1, 2024	1.43	-0.04	-2.72%	1.47	1.49	1.34
Mar 28, 2024	1.45	0.11	8.21%	1.34	1.57	1.31
Mar 27, 2024	1.37	0.11	8.73%	1.26	1.43	1.26
Mar 26, 2024	1.28	0.03	2.40%	1.25	1.32	1.24
Mar 25, 2024	1.25	0.04	3.31%	1.21	1.27	1.21
Mar 22, 2024	1.24	-0.05	-3.88%	1.29	1.35	1.24
Mar 21, 2024	1.33	0.13	10.83%	1.20	1.36	1.20

Lineage Cell Therapeutics, Inc. Events

Time (UTC)	Country	Event
Thursday, May 9, 2024
Time (UTC) 10:59	Country US	Event Q1 2024 Lineage Cell Therapeutics Inc Earnings Release Q1 2024 Lineage Cell Therapeutics Inc Earnings Release Forecast - Previous -
Tuesday, June 11, 2024
Time (UTC) 10:59	Country US	Event Lineage Cell Therapeutics Inc Annual Shareholders Meeting Lineage Cell Therapeutics Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 8, 2024
Time (UTC) 10:59	Country US	Event Q2 2024 Lineage Cell Therapeutics Inc Earnings Release Q2 2024 Lineage Cell Therapeutics Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	14.703	4.341	1.826	3.515	4.988
Revenue	14.703	4.341	1.826	3.515	4.988
Cost of Revenue, Total	0.728	1.426	0.385	0.412	0.302
Gross Profit	13.975	2.915	1.441	3.103	4.686
Total Operating Expense	37.223	53.029	28.273	42.391	-31.728
Selling/General/Admin. Expenses, Total	22.508	18.212	15.571	24.031	24.726
Research & Development	13.887	33.714	11.117	15.948	18.755
Unusual Expense (Income)	0	-0.523		0	-77.711
Operating Income	-22.52	-48.688	-26.447	-38.876	36.716
Interest Income (Expense), Net Non-Operating	-1.365	3.727	1.817	16.499	-82.531
Other, Net	-1.927	1.691	2.706	3.143	-1.315
Net Income Before Taxes	-25.812	-43.27	-21.924	-19.234	-47.13
Net Income After Taxes	-26.353	-43.27	-20.685	-11.827	-46.784
Minority Interest	0.08	0.251	0.036	0.118	0.794
Net Income Before Extra. Items	-26.273	-43.019	-20.649	-11.709	-45.99
Net Income	-26.273	-43.019	-20.649	-11.709	-45.99
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items	-26.273	-43.019	-20.649	-11.709	-45.99
Income Available to Common Incl. Extra. Items	-26.273	-43.019	-20.649	-11.709	-45.99
Dilution Adjustment
Diluted Net Income	-26.273	-43.019	-20.649	-11.709	-45.99
Diluted Weighted Average Shares	169.792	164.502	150.044	145.533	126.903
Diluted EPS Excluding Extraordinary Items	-0.15474	-0.26151	-0.13762	-0.08046	-0.3624
Diluted Normalized EPS	-0.15474	-0.26469	-0.13762	-0.08046	-0.75823
Depreciation / Amortization	0.1	0.2	1.2	2	2.2

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	3.225	2.386	1.915	2.998	4.553
Revenue	3.225	2.386	1.915	2.998	4.553
Cost of Revenue, Total	0.127	0.119	0.102	0.235	0.215
Gross Profit	3.098	2.267	1.813	2.763	4.338
Total Operating Expense	8.249	9.028	8.554	8.249	8.787
Selling/General/Admin. Expenses, Total	4.249	4.724	4.348	4.422	5.27
Research & Development	3.873	4.185	4.104	3.592	3.302
Depreciation / Amortization
Operating Income	-5.024	-6.642	-6.639	-5.251	-4.234
Interest Income (Expense), Net Non-Operating	0.232	0.45	-0.123	0.151	-0.658
Other, Net	-0.411	-0.015	0.4	-0.475	-1.89
Net Income Before Taxes	-5.203	-6.207	-6.362	-5.575	-6.782
Net Income After Taxes	-5.203	-4.404	-6.362	-6.116	-6.782
Minority Interest	-0.026	0.032	0.008	0.047	0.019
Net Income Before Extra. Items	-5.229	-4.372	-6.354	-6.069	-6.763
Net Income	-5.229	-4.372	-6.354	-6.069	-6.763
Income Available to Common Excl. Extra. Items	-5.229	-4.372	-6.354	-6.069	-6.763
Income Available to Common Incl. Extra. Items	-5.229	-4.372	-6.354	-6.069	-6.763
Diluted Net Income	-5.229	-4.372	-6.354	-6.069	-6.763
Diluted Weighted Average Shares	170.592	170.127	170.002	169.786	169.731
Diluted EPS Excluding Extraordinary Items	-0.03065	-0.0257	-0.03738	-0.03574	-0.03985
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.03065	-0.0257	-0.03738	-0.03574	-0.03985
Unusual Expense (Income)			0	0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	60	111.549	43.999	57.519	36.358
Cash and Short Term Investments	57.875	58.358	41.562	30.716	30.741
Cash & Equivalents	11.355	55.742	32.585	9.497	23.587
Short Term Investments	46.52	2.616	8.977	21.219	7.154
Total Receivables, Net	0.297	50.84	0.004	23.94	3.719
Accounts Receivable - Trade, Net	0.297	50.84	0.004	0.044	0.891
Prepaid Expenses	1.828	2.351	2.433	2.863	1.898
Total Assets	123.664	174.545	107.949	125.478	101.66
Property/Plant/Equipment, Total - Net	5.673	4.872	5.63	8.175	5.835
Property/Plant/Equipment, Total - Gross	11.523	10.174	9.945	12.766	9.02
Accumulated Depreciation, Total	-5.85	-5.302	-4.315	-4.591	-3.185
Intangibles, Net	46.692	46.822	47.032	48.248	3.125
Long Term Investments				0	33.733
Other Long Term Assets, Total	0.627	0.63	0.616	0.864	0.505
Total Current Liabilities	18.981	47.116	7.769	6.494	6.812
Accounts Payable	2.393	3.543	2.611	2.427	2.359
Accrued Expenses	7.131	25.049	4.416	3.985	4.332
Notes Payable/Short Term Debt	0	0	0.523	0	0
Current Port. of LT Debt/Capital Leases	0.036	0.03	0.016	0.033	0.07
Other Current Liabilities, Total	9.421	18.494	0.203	0.049	0.051
Total Liabilities	50.325	82.324	11.75	12.519	7.82
Total Long Term Debt	0.084	0.03	0.026	0.077	1.958
Long Term Debt					0
Capital Lease Obligations	0.084	0.03	0.026	0.077	1.958
Minority Interest	-1.403	-1.323	-1.072	-1.712	-1.594
Other Liabilities, Total	30.587	34.425	2.951	4.345	0.644
Total Equity	73.339	92.221	96.199	112.959	93.84
Preferred Stock - Non Redeemable, Net	0			0	0
Common Stock	440.28	434.529	393.944	387.062	354.27
Retained Earnings (Accumulated Deficit)	-363.37	-337.097	-294.078	-273.422	-261.856
Treasury Stock - Common
Other Equity, Total	-3.571	-5.211	-3.667	-0.681	1.426
Total Liabilities & Shareholders’ Equity	123.664	174.545	107.949	125.478	101.66
Total Common Shares Outstanding	170.093	169.477	153.096	149.804	127.136
Note Receivable - Long Term				0	22.104
Goodwill, Net	10.672	10.672	10.672	10.672
Deferred Income Tax	2.076	2.076	2.076	3.315

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	43.481	48.491	49.655	60	68.509
Cash and Short Term Investments	41.332	45.925	46.814	57.875	66.355
Cash & Equivalents	31.474	33.886	15.451	11.355	24.752
Short Term Investments	9.858	12.039	31.363	46.52	41.603
Total Receivables, Net	0.432	0.443	0.203	0.297	0.434
Accounts Receivable - Trade, Net	0.432	0.443	0.203	0.297	0.434
Prepaid Expenses	1.717	2.123	2.638	1.828	1.72
Total Assets	106.153	111.688	113.205	123.664	131.148
Property/Plant/Equipment, Total - Net	4.854	5.31	5.584	5.673	4.652
Property/Plant/Equipment, Total - Gross	11.448	11.693	11.694	11.523	10.464
Accumulated Depreciation, Total	-6.594	-6.383	-6.11	-5.85	-5.812
Goodwill, Net	10.672	10.672	10.672	10.672	10.672
Intangibles, Net	46.594	46.627	46.659	46.692	46.724
Other Long Term Assets, Total	0.552	0.588	0.635	0.627	0.591
Total Current Liabilities	15.881	16.052	17.225	18.981	22.739
Accounts Payable	2.43	2.187	3.001	2.393	2.865
Accrued Expenses	3.481	3.431	3.126	7.131	7.46
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0.055	0.054	0.051	0.036	0.025
Other Current Liabilities, Total	9.915	10.38	11.047	9.421	12.389
Total Liabilities	38.036	39.021	42.755	50.325	52.2
Total Long Term Debt	0.097	0.113	0.133	0.084	0.016
Capital Lease Obligations	0.097	0.113	0.133	0.084	0.016
Deferred Income Tax	0.273	0.273	0.273	2.076	2.076
Minority Interest	-1.457	-1.409	-1.435	-1.403	-1.395
Other Liabilities, Total	23.242	23.992	26.559	30.587	28.764
Total Equity	68.117	72.667	70.45	73.339	78.948
Common Stock	450.282	448.249	441.299	440.28	439.148
Retained Earnings (Accumulated Deficit)	-380.081	-372.971	-367.742	-363.37	-357.016
Other Equity, Total	-2.084	-2.611	-3.107	-3.571	-3.184
Total Liabilities & Shareholders’ Equity	106.153	111.688	113.205	123.664	131.148
Total Common Shares Outstanding	174.987	174.439	170.174	170.093	169.886
Preferred Stock - Non Redeemable, Net	0	0	0	0	0

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-26.273	-43.019	-20.649	-11.709	-45.99
Cash From Operating Activities	1.059	-23.561	-19.753	-31.947	-30.882
Cash From Operating Activities	0.582	0.663	0.895	1.131	1.081
Amortization	0.145	0.21	1.216	1.998	2.192
Deferred Taxes
Non-Cash Items	7.901	-2.511	-2.516	-21.464	11.197
Cash Interest Paid	0.013	0.013	0.02	0.028	0.155
Changes in Working Capital	18.704	21.096	1.301	-1.903	0.638
Cash From Investing Activities	-46.159	9.745	13.038	16.957	11.816
Capital Expenditures	-0.413	-0.354	-0.064	-0.44	-3.287
Other Investing Cash Flow Items, Total	-45.746	10.099	13.102	17.397	15.103
Cash From Financing Activities	1.632	36.93	29.865	0.617	5.774
Financing Cash Flow Items	-0.123	-1.155	-0.383	0.654	0.161
Issuance (Retirement) of Stock, Net	1.787	38.105	5.127	0.063	5.962
Issuance (Retirement) of Debt, Net	-0.032	-0.02	25.121	-0.1	-0.349
Foreign Exchange Effects	-0.873	-0.02	-0.063	0.07	0.006
Net Change in Cash	-44.341	23.094	23.087	-14.303	-13.286

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-4.372	-26.273	-19.919	-13.85	-7.087
Cash From Operating Activities	-11.242	1.059	9.362	14.842	21.904
Cash From Operating Activities	0.138	0.582	0.441	0.296	0.15
Amortization	0.033	0.145	0.113	0.065	0.032
Non-Cash Items	1.098	7.901	7.168	5.861	1.685
Cash Interest Paid	0.002	0.013	0.013	0.009	0.005
Changes in Working Capital	-8.139	18.704	21.559	22.47	27.124
Cash From Investing Activities	15.426	-46.159	-41.057	-0.143	-0.046
Capital Expenditures	-0.188	-0.413	-0.429	-0.143	-0.046
Other Investing Cash Flow Items, Total	15.614	-45.746	-40.628	0	0
Cash From Financing Activities	0.001	1.632	1.51	0.546	0.513
Financing Cash Flow Items	-0.037	-0.123	-0.112	-0.074	-0.008
Issuance (Retirement) of Stock, Net	0.051	1.787	1.645	0.635	0.529
Foreign Exchange Effects	-0.1	-0.873	-0.795	-0.161	-0.042
Net Change in Cash	4.085	-44.341	-30.98	15.084	22.329
Deferred Taxes			0	0
Issuance (Retirement) of Debt, Net	-0.013	-0.032	-0.023	-0.015	-0.008
Cash Taxes Paid	1.803

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Lineage Cell Therapeutics, Inc. Company profile

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company''s lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in clinical trial for the treatment of HIV-associated facial lipoatrophy; HyStem, a biomaterial used for cell replacement and retention; and Premvia, a Hystem Hydrogel product, as well as develops bone grafting products for the orthopedic diseases and injuries. In addition, the company offers various therapeutic products for the treatment of oncology, neurological diseases and disorders, blood and vascular system diseases and disorders, and blood plasma volume expansion, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Industry:

Biotechnology & Medical Research (NEC)

2173 Salk Ave Ste 200
CARLSBAD
CALIFORNIA 92008-7354
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024